Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
92%
Chimeric Antigen Receptor T-cell Therapy
88%
Relapsed or Refractory
76%
Large B-cell Lymphoma
50%
Cytokine Release Syndrome
44%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
43%
Overall Survival
32%
Non-relapse Mortality
31%
Refractory Diffuse Large B-cell Lymphoma
27%
Hazard Ratio
27%
Non-Hodgkin Lymphoma
24%
CD19
23%
B-cell Malignancies
22%
Antigen Loss
22%
Progression-free Survival
20%
High Risk
20%
Lymphoma Patients
20%
Lymphoma
19%
Myeloma
19%
Autologous Transplantation
19%
Confidence Interval
16%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
16%
Multispecific
16%
Thiotepa
16%
Dose Intensity
16%
Non-covalent
16%
Peripheral Neuropathy
16%
Loncastuximab Tesirine
16%
Bcl-w
16%
Brentuximab Vedotin
16%
Primary Diffuse Large B-cell Lymphoma
16%
B-cell Lymphoma 2 (Bcl-2)
16%
Systematic Meta-analysis
16%
Bispecific Antibody
16%
Corticosteroids
16%
Relapsed or Refractory Diffuse Large B-cell Lymphoma
16%
Leukemia Patients
16%
Meta-analysis
16%
Venetoclax
16%
Alternative Protein
16%
Chronic Lymphocytic Leukemia
16%
Carmustine
16%
Gastrointestinal Diseases
16%
Hodgkin Lymphoma
16%
Bruton Tyrosine Kinase Inhibitor
16%
Anaplastic Large Cell Lymphoma
16%
COVID-19
16%
Clinical Data
16%
Prognostic Impact
16%
Early Cytokines
16%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell
97%
Chimeric Antigen Receptor T-Cell Immunotherapy
79%
Cytokine Release Syndrome
46%
B Cell
39%
Chimeric Antigen Receptor
36%
Large-Cell Lymphoma
33%
Cancer
27%
Diseases
27%
Hazard Ratio
27%
Hematopoietic Cell
26%
Non-Relapse Mortality
20%
Infusion
19%
Non-Hodgkin Lymphoma
19%
CD20
19%
Toxicity and Intoxication
19%
Effector Cell
19%
Myeloma
18%
Brentuximab Vedotin
16%
Hodgkin's Lymphoma
16%
Meta-Analysis
16%
Montelukast
16%
Neuropathy
16%
Bispecific Antibody
16%
Systematic Review
16%
Transplantation
16%
Anaplastic Large Cell Lymphoma
16%
Immunity
16%
COVID-19
16%
Prevalence
16%
Gastrointestinal Distress
16%
Remote Sensing
16%
Outpatient
16%
B-Cell Lymphoma
16%
Loncastuximab
16%
Mantle Cell Lymphoma
16%
Progression Free Survival
16%
Infection
15%
Cell Transplantation
14%
Overall Survival
14%
Clinical Trial
12%
Neoplasm
12%
Phase I Trials
11%
Hemophagocytic Syndrome
8%
B Cell Maturation Antigen
8%
Recurrence Risk
8%
Cytotoxicity
8%
Aplasia
7%
T Cell
6%
Immunotherapy
6%
Hypogammaglobulinemia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chimeric Antigen Receptor
100%
Cytokine Release Syndrome
35%
Diffuse Large B Cell Lymphoma
33%
Large Cell Lymphoma
33%
Nonhodgkin Lymphoma
22%
Diseases
20%
Myeloma
18%
Toxicity and Intoxication
18%
Overall Survival
17%
Loncastuximab Tesirine
16%
Thiotepa
16%
Brentuximab Vedotin
16%
Coronavirinae
16%
Neuropathy
16%
Venetoclax
16%
Prevalence
16%
Gastrointestinal Symptom
16%
Carmustine
16%
Bispecific Antibody
16%
Bruton Tyrosine Kinase Inhibitor
16%
Chronic Lymphatic Leukemia
16%
Hodgkin Disease
16%
B Cell Lymphoma
16%
Mantle Cell Lymphoma
16%
Infection
15%
Progression Free Survival
13%
CD19 Antibody
11%
Clinical Trial
9%
B Cell Maturation Antigen
8%
Immunotherapy
6%
Malignant Neoplasm
6%
Hypertransaminasemia
5%
Antibody Drug Conjugate
5%
Thrombocytopenia
5%
Neutropenia
5%
Alkylating Agent
5%
Pharmacokinetic
5%
Disease Exacerbation
5%
Neoplasm
5%
Retrospective Study
5%
